Oncotarget runs under the most outstanding scientist all around the world. It is a traditional journal that publishes scientific articles and journals using an online platform on a weekly basis. The topics of the materials and periodicals range widely from different scientific disciplines. The term Oncotarget covers most cellular and molecular functions joint in aging and cancer, lymphocytes and neurons, microbes, cancer cells, atherosclerosis, and neurodegeneration.
Oncotarget aims to the availability of scientific results easy and accessible. It also aims to capitalize on the impact of scientific research using informative and factual reviews and also enables timely publication of extraordinary discoveries. This platform also seeks to connect the various ground of biomedical science and drive applications of clinical psychology to fight diseases.
Oncotarget currently accepts papers from different topics and is not only limited to Oncology. Its popularity lies in the fact that it gives valuable, articulate, punctual and insightful information and the authors can create an extraordinary outcome of their research. As a business, Oncotarget makes two publications in a week, and that gives more different authors a platform to write and publish their work. The online editions continually changing from one insightful topic to the other have managed to gain loyal users of the site and new visits to the site on a daily basis and more
Recent publications on the Oncotarget were under Autophagy and cell death. The topics were broken down to many subtopics like the Mitotic catastrophe and Accidental cell deaths. These questions thoroughly researched and discussed the publications have been of vital importance to researchers. Other current publications include papers on; Intentional weight loss and cancer risk, community mining of open clinical trial data, the outcome of patients treated for a myelodysplastic syndrome with 5q deletions after the failure of lenalidomide therapy among other informative articles, review, and journals.
Still, in recent activities, InteGragen announced Publication in Oncotarget as a sign of association in various capacities. IntegraGen specializes in the transforming data from biological samples into diagnostic tools for oncology and genomic information for the same purpose. The announcement was as a result of a previous analysis of miR-31-3P that confirmed its relationship to the effectiveness of anti-EGFR treatment.